WASHINGTON — Nearly a dozen Democratic senators aren’t yet willing to publicly support President Biden’s Food and Drug Administration pick, Robert Califf, despite his sailing through a key health committee vote earlier this month.
It’s a surprising level of uncertainty for Califf, who earned almost unanimous support when he was confirmed to lead the same agency in 2016.
And it’s surprising, too, given the power that the FDA has to shape the response to the Covid-19 pandemic — a response for which Biden is increasingly being criticized. The FDA, which is responsible for evaluating the safety of Covid-19 tests, vaccines, and therapeutics, has been without a Senate-confirmed leader for more than a year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.